Literature DB >> 11397710

Endogenous neutralizing antibodies against platelet-derived growth factor-aa inhibit atherogenesis in the cholesterol-fed rabbit.

D J Lamb1, T Y Avades, G A Ferns.   

Abstract

Previous studies have shown that the B chain of platelet-derived growth factor (PDGF) has an important role in atherogenesis. In this study we have investigated the contribution of PDGF-A chain in cholesterol-induced atherogenesis in the New Zealand White rabbit. High titers of antibodies to PDGF-AA or to platelet cytosolic protein (PCP) were induced in these animals by immunization against recombinant human PDGF-AA or human PCP. Rabbits were then fed a 0.25% to 1% cholesterol-containing diet for 10 weeks to induce atherosclerotic lesions; the rabbits were then humanely killed and perfusion-fixed and their aortas were removed. The extent of atherosclerosis in the thoracic aortas was determined by quantitative morphometry after staining with oil red O. The intimal and medial areas in histological sections taken at the level of the first intercostal branch were quantified by image analysis. Immunization against PDGF-AA and PCP, but not against adjuvant alone, resulted in rising titers of antibodies within 2 weeks, the levels of which reached a plateau by 8 weeks. The antibodies to PDGF-AA were isoform-specific, recognized both human and rabbit PDGF-AA, and neutralized the biological activity of PDGF-AA in vitro. Integrated plasma cholesterol levels were similar in both groups. Compared with nonimmune rabbits (n=10), animals immunized against PDGF-AA (n=10) or PCP (n=10) had significantly smaller areas of the aorta covered by atherosclerotic lesions (24.6+/-5.1% and 18.7+/-4.2%, respectively, vs 34.4+/-4.3%; P<0.05). This was associated with a reduced aortic intimal-medial area ratio in PDGF-AA-immunized (0.009+/-0.006) and PCP-immunized (0.025+/-0.017) rabbits than in nonimmune animals (0.159+/-0.066; P<0.05). These data suggest that PDGF-AA is actively involved in cholesterol-induced atherosclerosis in the rabbit.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397710     DOI: 10.1161/01.atv.21.6.997

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice.

Authors:  Koichi Kozaki; Wolfgang E Kaminski; Jingjing Tang; Stan Hollenbach; Per Lindahl; Carol Sullivan; Jin-Chen Yu; Keith Abe; Paul J Martin; Russell Ross; Christer Betsholtz; Neill A Giese; Elaine W Raines
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

2.  Platelet-derived growth factor and platelet profiles in childhood nephrotic syndrome.

Authors:  Anna M Wasilewska; Walentyna M Zoch-Zwierz; Barbara Tomaszewska; Anna Biernacka
Journal:  Pediatr Nephrol       Date:  2004-10-13       Impact factor: 3.714

3.  Vascular smooth muscle cell motility: From migration to invasion.

Authors:  Sherif F Louis; Peter Zahradka
Journal:  Exp Clin Cardiol       Date:  2010

4.  Activation of the GTPase ARF6 regulates invasion of human vascular smooth muscle cells by stimulating MMP14 activity.

Authors:  Emilie Fiola-Masson; Julie Artigalas; Shirley Campbell; Audrey Claing
Journal:  Sci Rep       Date:  2022-06-09       Impact factor: 4.996

5.  Nox5 mediates PDGF-induced proliferation in human aortic smooth muscle cells.

Authors:  Desmond B Jay; Christopher A Papaharalambus; Bonnie Seidel-Rogol; Anna E Dikalova; Bernard Lassègue; Kathy K Griendling
Journal:  Free Radic Biol Med       Date:  2008-04-26       Impact factor: 7.376

Review 6.  Vaccination and atherosclerosis.

Authors:  Xinghua Zhou; Göran K Hansson
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

7.  Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside.

Authors:  Ana Villegas; Fernando A Gonzalez; Leopoldo Llorente; Santiago Redondo
Journal:  Biologics       Date:  2008-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.